Tryvio™
Drug - Tryvio™ (aprocitentan) [Idorsia Pharmaceuticals Ltd]
June 2025
Therapeutic Area - Antihypertensives, Other
Initial approval criteria
- Patient has a diagnosis of hypertension AND
- Patient is at least 18 years of age AND
- Patient is still not at blood pressure goal while on triple agent therapy with 3 different antihypertensive therapy classes OR
- Patient is unable to be on triple antihypertensive therapy with 3 different antihypertensive therapy classes AND
- Patient will continue therapy with another antihypertensive agent in combination with Tryvio AND
- Patient does NOT have any FDA labeled contraindications to Tryvio
- Initial approval is for 3 months
Renewal criteria
- Patient has had clinical benefit with Tryvio AND
- Patient will continue therapy with another antihypertensive agent in combination with Tryvio AND
- Patient does NOT have any FDA labeled contraindications to the requested agent
- Renewal approval is for 12 months
Quantity limits
30 tablets per 30 days
Quetsions?
Provider Call Center (844) 575-7887
